Jornal Vascular Brasileiro
https://jvascbras.org/article/doi/10.1590/1677-5449.190159
Jornal Vascular Brasileiro
Case Report

Uso de tartarato de brimonidina para resolução de matting telangiectásico: relato de caso

Use of brimonidine tartrate to resolve telangiectatic matting: case report

Brenno Augusto Seabra de Mello Netto; Yasmin de Rezende Beiriz; Américo Carnelli Bonatto; Gustavo Sasso Benso Maciel; Laila Reggiani de Almeida; José Marcelo Corassa

Downloads: 2
Views: 50

Resumo

Resumo: A escleroterapia é, atualmente, o tratamento de escolha para telangiectasias e veias reticulares, apresentando nível de recomendação 1ª pela diretriz europeia para escleroterapia. Os efeitos colaterais mais comuns desse procedimento são a hiperpigmentação e o matting telangiectásico, sendo este último um dos mais temidos em virtude do dano estético e da dificuldade de tratamento. O matting se refere a vasos com diâmetro inferior a 0,2 mm que podem surgir esporadicamente ou em áreas bem definidas, principalmente nos membros inferiores. Este relato apresenta um caso de matting tratado com o uso de tartarato de brimonidina tópico.

Palavras-chave

escleroterapia, telangiectasia, varizes, relato de caso

Abstract

Sclerotherapy is currently the treatment of choice for telangiectasias and reticular veins, with grade 1A recommendation in the European Guideline for sclerotherapy. The most common side effects of this procedure are hyperpigmentation and telangiectatic matting, the second of which provokes great concern because of the esthetic damage and the difficulty of treatment. Matting refers to vessels with a diameter of less than 0.2 mm, which may emerge irregularly or in well-defined areas, especially on the lower limbs. This report presents a case of matting treated with topical Brimonidine Tartrate.

Keywords

sclerotherapy; telangiectasis; varicose veins. case report.

References

1 França LH, Tavares V. Insuficiência venosa crônica: uma atualização. J Vasc Bras. 2003;2(4):18-28.

2 Castro e Silva M, Cabral ALS, Barros N Jr, Castro AA, Santos MERC. Diagnóstico e tratamento da doença venosa crônica. J Vasc Bras. 2005;4(3):S185-94.

3 Jia X, Mowatt G, Burr JM, Cassar K, Cook J, Fraser C. Systematic review of foam sclerotherapy for varicose veins. Br J Surg. 2007;94(8):925-36. http://dx.doi.org/10.1002/bjs.5891. PMid:17636511.

4 Yiannakopoulou E. Safety concerns for sclerotherapy of telangiectases, reticular and varicose veins. Pharmacology. 2016;98(1-2):62-9. http://dx.doi.org/10.1159/000445436. PMid:27104778.

5 Kadam P, Lim J, Paver I, Connor DE, Parsi K. Telangiectatic matting is associated with hypersensitivity and a bleeding tendency. Eur J Vasc Endovasc Surg. 2018;55(4):554-9. http://dx.doi.org/10.1016/j.ejvs.2017.12.013. PMid:29409702.

6 Goldman MP, Martin DE, Fitzpatrick RE, Ruiz-Esparza J. Pulsed dye laser treatment of telangiectases with and without subtherapeutic sclerotherapy. J Am Acad Dermatol. 1990;23(1):23-30. http://dx.doi.org/10.1016/0190-9622(90)70180-P. PMid:2365873.

7 Sadick NS, Urmacher C. Estrogen and progesterone receptors: their role in postsclerotherapy angiogenesis telangiectatic matting (TM). Dermatol Surg. 1999;25:7. http://dx.doi.org/10.1046/j.1524-4725.1999.99026.x. PMID: 10469110.

8 Davis LT, Duffy DM. Determination of incidence and risk factors for postsclerotherapy telangiectatic matting of the lower extremity: a retrospective analysis. J Dermatol Surg Oncol. 1990;16(4):327-30. http://dx.doi.org/10.1111/j.1524-4725.1990.tb00043.x. PMid:1691217.

9 Goldman MP, Sadick NS, Weiss RA. Cutaneous necrosis, telangiectatic matting, and hyperpigmentation following sclerotherapy. Etiology, prevention, and treatment. Dermatol Surg. 1995;21(1):19-29, quiz 31-2. http://dx.doi.org/10.1111/j.1524-4725.1995.tb00107.x. PMid:7600016.

10 Mann MW. Sclerotherapy: it is back and better. Clin Plast Surg. 2011;38(3):475-87, vii. http://dx.doi.org/10.1016/j.cps.2011.02.006. PMid:21824544.

11 Parlar B, Blazek C, Cazzaniga S, et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. J Eur Acad Dermatol Venereol. 2015;29(3):549-54. http://dx.doi.org/10.1111/jdv.12627. PMid:25069999.

12 Del Rosso JQ. Management of facial erythema of rosacea: what is the role of topical a-adrenergic receptor agonist therapy. J Am Acad Dermatol. 2013;69(6, Suppl 1):44-56. http://dx.doi.org/10.1016/j.jaad.2013.06.009. PMid:24229637.

13 Lowe E, Lim S. Paradoxical erythema reaction of long-term topical brimonidine gel for the treatment of facial erythema of rosacea. J Drugs Dermatol. 2016;15(6):763-5. PMid:27272086.
 


Submitted date:
01/16/2020

Accepted date:
05/01/2020

5f6a16e90e882523269fefc6 jvb Articles

J Vasc Bras

Share this page
Page Sections